Effect of rectal administration of rebamipide on dextran sulfate sodium-induced colitis: role of hepatocyte growth factor.
OBJECTIVE
Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.


METHODS
Fifty-five and forty female Balb/c mice, respectively, were used in Exp. 1 and 2.


METHODS
50 mg/kg/day rebamipide (Exp. 1) and 1 x 10(7) pfu pAxCAHGF (the CAG promoter-driving HGF gene in adenovirus vector) (Exp. 2) were intrarectally introduced after induction of colitis by 4 % dextran sulfate sodium (DSS).


METHODS
Therapeutic effects were assessed by cell proliferation and apoptosis.


RESULTS
Rebamipide caused proliferation of epithelial cells at 10 days after treatment, and decreased apoptosis at 10, 14 and 21 days, compared with controls. Expression of HGF was greatly increased in rebamipide-treated mice. pAxCAHGF caused cell proliferation and apoptosis, which showed the same pattern as with rebamipide treatment.


CONCLUSIONS
Rectal administration of rebamipide is effective for DSS-induced colitis in association with induction of HGF.
Murai
R
R
Division of Molecular and Genetic Medicine, Department of Genetic Medicine and Regenerative Therapeutics, Graduate School of Medicine, Tottori University, Yonago 683-8504, Japan.
Kanbe
T
T
Mukoyama
T
T
Shimomura
T
T
Hashiguchi
K
K
Yoshida
Y
Y
Tsuchiya
H
H
Hoshikawa
Y
Y
Kurimasa
A
A
Shiota
G
G
D000285:Administration, Rectal; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000925:Anticoagulants / Q000633:toxicity; D017209:Apoptosis; D049109:Cell Proliferation; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016264:Dextran Sulfate / Q000633:toxicity*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D004847:Epithelial Cells / Q000166:cytology; D005260:Female; D017228:Hepatocyte Growth Factor / Q000378:metabolism*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D051379:Mice; D008807:Mice, Inbred BALB C; D015363:Quinolones / Q000008:administration & dosage*
D000925:Anticoagulants; D004791:Enzyme Inhibitors; D015363:Quinolones; D017228:Hepatocyte Growth Factor; D016264:Dextran Sulfate; C052785:rebamipide; D000409:Alanine